Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer
Abstract
Photodynamic therapy (PDT) is based on the association of a light source and light sensitive agents in order to cause the selective death of tumor cells. To evaluate topical 5-aminolaevulinic acid (5-ALA) and diode laser photodynamic single session therapy single session for non-melanoma skin cancer (NMSC), a long-term follow-up was performed. Nineteen Bowen's disease (BD) and 15 basal cell carcinoma (BCC) lesions were submitted to 6-h topical and occlusive 20% 5-ALA plus DMSO and EDTA, and later were exposed to 630 nm diode laser, 100 or 300 J cm(-2) dose. At 3 months tumor-free rate was 91.2% (31/34) whereas at 60 months, 57.7% (15/26), slightly higher in BCC (63.6%; 7/11). The relation between the reduction of the clinical response and the increase of tumor dimension observed at 18 months was lost at 60 months. The sBCC recurrence was earlier compared to the nBCC one. ALA-PDT offered important advantages: it is minimally invasive, an option for patients under risk of surgical complications; clinical feasibility; treatment of multiple lesions in only one session or lesions in poor healing sites and superior esthetical results. However, the recurrence rate increase after ALA-PDT diode laser single session can be observed at long-term follow-up, and the repetitive sessions, an additional advantage of the method, is strongly recommended. The clinical response and recurrence time seem to be related to the laser light dose and NMSC types/sub-types, thickness and dimension, which must be considered for the choice of the ALA-PDT.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
60 months after treatment the recurrence rate reaches as much as 43%.
“Unfortunately, 60 months after the treatment the recurrence rate reaches as much as 43% [114].”
From Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer (2011) · cites this paper as [114]
The citation lists haven’t been fetched yet
References 33 · Cited by 71
- Authors
- Souza, C. S., Felicio, L. B. A., Ferreira, J., Kurachi, C., Bentley, M. V. B., Tedesco, A. C., & Bagnato, V. S.
- Affiliations
- Universidade de São Paulo (BR)
- Venue
- Photodiagnosis and Photodynamic Therapy
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 6
- Issue
- 3-4
- Pages
- 207-213
- ISSN
- 1572-1000 (ISSN-L)
- OpenAlex
- W2028971832
- Cited by
- 71
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 7 · 2015: 3 · 2014: 4 · 2013: 11 · 2012: 9
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Photodiagnosis and Photodynamic Therapy (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Topics
- Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- 5-aminolevulinic acid, photodynamic therapy, diode laser, non-melanoma skin cancer, basal cell carcinoma, Bowen's disease, tumor recurrence, long-term follow-up
- MeSH terms
- Administration, Topical, Adult, Aged, Aminolevulinic Acid, Bowen's Disease, Basal Cell Carcinoma, Carcinoma, Basal Cell, Female, Follow-Up Studies, Humans, Male, Middle Aged, Photochemotherapy, Prospective Studies, Skin Neoplasms, Time Factors, Lasers, Semiconductor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review